CytomX Therapeutics (CTMX) AI Stock Analysis

• Market Cap: $336.42M
• Dividend Yield: N/A
• Average Volume (3M): 3.09M
• Price to Earnings (P/E): 3.6
• Beta (1Y): 3.00
• Revenue Growth: 18.01%
• EPS Growth: 306.76%
• Country: US
• Employees: 119
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): 0.00
• Shares Outstanding: 164,912,900
• 10 Day Avg. Volume: 2,995,729
• 30 Day Avg. Volume: 3,091,037
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.42
• Enterprise Value/Revenue: 0.96
• Enterprise Value/Gross Profit: 0.96
• Enterprise Value/Ebitda: 3.77
• 1Y Price Target: $5.30
• Price Target Upside: 154.81% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 61 Neutral
• Price Target: $2.00 ▼(-3.85% Downside)

CytomX Therapeutics' overall stock score is driven by a strong valuation due to its low P/E ratio, indicating potential undervaluation. Financial performance shows operational improvements but is weighed down by significant balance sheet and cash flow challenges. Technical analysis suggests a neutral trend with moderate momentum. The earnings call provided positive clinical updates and a solid financial position, although revenue decline and adverse events pose risks.

Positive Factors

Clinical Trial Results

CytomX reported highly promising dose escalation data for CX-2051 in mCRC with an ORR of 28% and impressive durability.

Financial Performance

CytomX reported no net loss or $0/share, which was above the estimate of ($0.14).

Negative Factors

Risks and Challenges

Risks include potential clinical trial delays and failure to generate favorable clinical data, particularly with CX-2051 in CRC.

Stock Market Reaction

The market has reacted negatively to the development, with shares of CytomX down approximately 20% since the press release.

CytomX Therapeutics Business Overview & Revenue Model

Company Description

CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on advancing a new class of cancer therapeutics known as Probody therapeutics. These innovative therapies are designed to selectively target tumors while sparing healthy tissue, thereby potentially reducing side effects associated with traditional cancer treatments. The company operates primarily within the oncology sector and is developing a pipeline of proprietary and partnered therapeutics that leverage its Probody platform to enhance the efficacy and safety of existing cancer therapies.

How the Company Makes Money

CytomX Therapeutics generates revenue through a combination of collaborations, licensing agreements, and potential product sales. The company has established partnerships with major pharmaceutical firms, which often involve upfront payments, milestone payments based on the achievement of specific development goals, and royalties on future product sales. These collaborations allow CytomX to fund its research and development while sharing the financial risks associated with bringing new therapies to market. Additionally, if its Probody therapeutics successfully progress through clinical trials and receive regulatory approval, CytomX stands to earn significant revenue from the commercialization of these products.

CytomX Therapeutics Financial Statement Overview

Summary

CytomX Therapeutics has shown positive revenue growth and improved profitability margins, indicating operational recovery. However, negative equity, potential solvency risks, and cash flow difficulties present significant financial instability.

Income Statement

CytomX Therapeutics showed a positive revenue growth rate from 2023 to 2024, with total revenue increasing from $101.21 million to $138.10 million, representing a growth rate of approximately 36.4%. The gross profit margin remained strong at 100% due to no cost of goods sold. However, the net profit margin improved significantly in 2024, reaching approximately 23.1%, compared to a negative margin in 2023. The EBIT and EBITDA margins also turned positive, indicating improved operational efficiency. Despite these improvements, historical volatility and past losses present a risk.

Balance Sheet

The balance sheet reflects a concerning negative equity position in 2024, with stockholders' equity at -$456,000, indicating liabilities exceed assets. The debt-to-equity ratio is not calculable due to negative equity, but total debt decreased over the year. The equity ratio is negative, which poses a significant risk to financial stability. This indicates potential solvency issues despite reducing total debt.

Cash Flow

The cash flow statement shows a deterioration in free cash flow from -$56.88 million in 2023 to -$86.54 million in 2024, indicating a decline in cash generation capabilities. The operating cash flow to net income ratio is negative, suggesting challenges in converting income into cash. Free cash flow to net income is also negative, highlighting cash flow difficulties despite positive net income in 2024. The high variability in cash flows suggests potential liquidity issues.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	138.10M	101.21M	53.16M	69.57M	100.36M
Gross Profit	138.10M	101.21M	47.31M	63.73M	100.36M
EBITDA	26.76M	-4.31M	-98.89M	-113.34M	-77.97M
Net Income	31.87M	-569.00K	-97.30M	-80.65M	-32.88M
Balance Sheet
Total Assets	120.53M	201.79M	260.89M	339.41M	358.66M
Cash, Cash Equivalents and Short-Term Investments	100.62M	174.51M	193.65M	305.23M	316.12M
Total Debt	9.38M	13.97M	18.06M	18.06M	24.87M
Total Liabilities	120.99M	249.24M	346.64M	250.03M	308.86M
Stockholders Equity	-456.00K	-47.45M	-85.75M	89.38M	49.80M
Cash Flow
Free Cash Flow	-86.54M	-56.88M	-112.53M	-120.64M	2.95M
Operating Cash Flow	-86.23M	-56.03M	-110.79M	-119.03M	5.26M
Investing Cash Flow	99.70M	-150.67M	98.26M	22.49M	-18.72M
Financing Cash Flow	7.52M	30.23M	648.00K	110.21M	16.89M

CytomX Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.08
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTMX, the sentiment is Positive. The current price of 2.08 is above the 20-day moving average (MA) of 2.06, below the 50-day MA of 2.24, and above the 200-day MA of 1.41, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 48.43 is Neutral, neither overbought nor oversold. The STOCH value of 51.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CTMX.

CytomX Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTMX	61 Neutral	$336.42M	3.64	108.21%	―	18.01%	306.76%
Sector *	51 Neutral	$7.86B	-0.33	-41.57%	2.23%	23.26%	-2.03%
PDSB	50 Neutral	$57.83M	―	-156.16%	―	―	25.26%
ARTV	46 Neutral	$76.94M	―	-86.18%	―	―	―
CUE	45 Neutral	$59.96M	―	-195.55%	―	-0.11%	43.47%
GUTS	42 Neutral	$70.11M	―	-379.75%	―	-85.71%	66.38%
ACRV	36 Underperform	$42.15M	―	-47.87%	―	―	18.86%

CytomX Therapeutics Corporate Events

CytomX Therapeutics Updates on CX-2051 Phase 1 Study

On August 13, 2025, CytomX Therapeutics announced an update on its CX-2051 Phase 1 study, detailing dose expansions and a treatment-related incident. Despite a Grade 5 acute kidney injury in a patient, the study continues with support from the Safety Review Committee, and a data update is expected by Q1 2026.

CytomX Therapeutics Approves Key Amendments at Annual Meeting

On June 11, 2025, CytomX Therapeutics held its Annual Meeting of Stockholders, where key amendments to the company’s equity and stock purchase plans were approved. The amendments included increasing the number of shares available under the 2015 Equity Incentive Plan, removing the evergreen provision, and extending the Employee Stock Purchase Plan indefinitely. Additionally, stockholders elected new directors, ratified the selection of Ernst & Young LLP as the independent auditor, and approved executive compensation.